Skip to content

Study · Animal study (in vivo) · mouse, rabbit and rat · 2010

10 results

[Preclinical safety investigation of GB-115 dipeptide].

Sorokina AV, Alekseeva SV, Nemova EP, Kovalenko LP, Smol'nikova NM, Shipaeva EV, Shreder OV, Miroshkina IA, Diukova SA, Daugel'-Dauge NO, Kulakova AV, Kolik LG, Durnev AD, Seredenin SB

Eksperimental'naia i klinicheskaia farmakologiia1 Jun 2010

PMID20726348 (opens in a new tab)PepBankPUB-20726348
Publisher pageAsk about this study
Jump to 10 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study10

10 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Safety outcome

    In mice, no animals died after acute oral GB‑115 at 6000 mg/kg.

    In plain wordsIn mice, no animals died after an acute oral GB‑115 dose of 6000 mg/kg.

    Peptide
    GB-115
    Outcome
    Not applicableAcute mortality
    Study

    mousen: not reported in source

    Preclinical safety tests
    Outcome group
    Mortality · Whole body
    Studied dose
    6000 mg/kg · oralAs given in this study (mouse).

    Source sentences

    Summary
    No animals were lost after GB-115 acute oral administration at a maximum dose of 6000 mg/kg in mice and at 3500 mg/kg in rats.
  2. 02AnimalAnimal study (in vivo)Safety outcome

    In rats, no animals died after acute oral GB‑115 at 3500 mg/kg.

    In plain wordsIn rats, no animals died after an acute oral GB‑115 dose of 3500 mg/kg.

    Peptide
    GB-115
    Outcome
    Not applicableAcute mortality
    Study

    ratn: not reported in source

    Preclinical safety tests
    Outcome group
    Mortality · Whole body
    Studied dose
    3500 mg/kg · oralAs given in this study (rat).

    Source sentences

    Summary
    No animals were lost after GB-115 acute oral administration at a maximum dose of 6000 mg/kg in mice and at 3500 mg/kg in rats.
  3. 03AnimalAnimal study (in vivo)Safety outcome

    In rabbits and rats of both sexes, oral GB‑115 for 6 months induced no irreversible pathological changes in studied organs and systems.

    In plain wordsIn rabbits and rats, oral GB‑115 for 6 months caused no irreversible pathological changes in the organs and systems studied.

    Peptide
    GB-115
    Outcome
    No significant changeIrreversible pathological changes
    Study

    rabbit and ratn: not reported in source

    Preclinical safety tests
    Outcome group
    Adverse events · Whole body
    Studied dose
    0.1 and 10 mg/kg · oral · 6 monthsAs given in this study (rabbit and rat).

    Source sentences

    Summary
    GB-115 administered per os during 6 months in rabbits and rats (both males and females) at the doses of 0.1 and 10 mg/kg induced no irreversible pathological changes in organs and systems studied.
  4. 04AnimalAnimal study (in vivo)Safety outcome

    In preclinical tests, GB‑115 did not affect generative function.

    In plain wordsIn animal safety tests, GB‑115 did not affect reproductive function.

    Peptide
    GB-115
    Outcome
    No significant changeGenerative function
    Study

    n: not reported in source

    Preclinical safety tests
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The tested dipeptide exhibited no allergenic, immunotoxic and mutagenic activity, and did not affect generative function and the antenatal and postnatal development of progeny.
  5. 05AnimalAnimal study (in vivo)Safety outcome

    In preclinical tests, GB‑115 did not affect antenatal development of progeny.

    In plain wordsIn animal safety tests, GB‑115 did not affect offspring development before birth.

    Peptide
    GB-115
    Outcome
    No significant changeAntenatal progeny development
    Study

    n: not reported in source

    Preclinical safety tests
    Outcome group
    Adverse events · Whole body
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The tested dipeptide exhibited no allergenic, immunotoxic and mutagenic activity, and did not affect generative function and the antenatal and postnatal development of progeny.
  6. 06AnimalAnimal study (in vivo)Safety outcome

    In preclinical tests, GB‑115 did not affect postnatal development of progeny.

    In plain wordsIn animal safety tests, GB‑115 did not affect offspring development after birth.

    Peptide
    GB-115
    Outcome
    No significant changePostnatal progeny development
    Study

    n: not reported in source

    Preclinical safety tests
    Outcome group
    Adverse events · Whole body
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The tested dipeptide exhibited no allergenic, immunotoxic and mutagenic activity, and did not affect generative function and the antenatal and postnatal development of progeny.
  7. 07AnimalAnimal study (in vivo)Efficacy outcome

    In preclinical tests, GB‑115 suppressed the inflammatory reaction to concanavalin A.

    In plain wordsIn animal tests, GB‑115 reduced the inflammatory reaction to concanavalin A.

    Peptide
    GB-115
    Outcome
    DecreaseConcanavalin A inflammatory reaction
    Study

    n: not reported in source

    Preclinical safety tests
    Outcome group
    Inflammation markers · Immune and inflammation
    Studied dose
    10 mg/kgAs given in this study.

    Source sentences

    Summary
    GB-115 at a dose of 10 mg/kg produced suppression of the inflammatory reaction to concanavalin A.
  8. 08AnimalOther designSafety outcome

    In preclinical tests, GB‑115 exhibited no allergenic activity.

    In plain wordsIn preclinical safety tests, GB‑115 showed no allergenic activity.

    Peptide
    GB-115
    Outcome
    No significant changeAllergenic activity
    Study

    n: not reported in source

    Preclinical safety tests
    Outcome group
    Adverse events · Whole body
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The tested dipeptide exhibited no allergenic, immunotoxic and mutagenic activity, and did not affect generative function and the antenatal and postnatal development of progeny.
  9. 09AnimalOther designSafety outcome

    In preclinical tests, GB‑115 exhibited no immunotoxic activity.

    In plain wordsIn preclinical safety tests, GB‑115 showed no immunotoxic activity.

    Peptide
    GB-115
    Outcome
    No significant changeImmunotoxic activity
    Study

    n: not reported in source

    Preclinical safety tests
    Outcome group
    Adverse events · Whole body
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The tested dipeptide exhibited no allergenic, immunotoxic and mutagenic activity, and did not affect generative function and the antenatal and postnatal development of progeny.
  10. 10AnimalOther designSafety outcome

    In preclinical tests, GB‑115 exhibited no mutagenic activity.

    In plain wordsIn preclinical safety tests, GB‑115 showed no mutagenic activity.

    Peptide
    GB-115
    Outcome
    No significant changeMutagenic activity
    Study

    n: not reported in source

    Preclinical safety tests
    Outcome group
    Adverse events · Whole body
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The tested dipeptide exhibited no allergenic, immunotoxic and mutagenic activity, and did not affect generative function and the antenatal and postnatal development of progeny.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    27 Oct 2026, 18:20 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:32 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.